PML Risk Stratification in Multiple Sclerosis Patients on Natalizumab

Stratify risk of developing PML in patients with Multiple Sclerosis who are on natalizumab

The global unit selector only affects unanswered questions
1.Does the patient have positive JC virus antibody, using 2 step ELISA method?
2.Is there a prior history of immunosuppression?
3.Has the patient been on natalizumab for more than 2 years (24 infusions)?
Created by

1. Does the patient have positive JC virus antibody, using 2 step ELISA method?

Created by
0/3 completed

About this Calculator

Natalizumab is a monoclonal antibody that targets the a4 subunit of the a4b1 adhesion molecule with established clinical efficacy. It is infused monthly. The principal risk in use of natalizumab is that of development of Progressive Multifocal Encephalopathy (PML), a devastating brain parenchymal infection with no current treatment. Three main risk factors have been elucidated: JC virus antibody status, history of previous immunosuppression, and duration of natalizumab treatment (less than or greater than 2 years). If PML is suspected, the drug should be stopped.

References

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, and Bozic C.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

New England Journal of Medicine 2012 May 17, 366 (20): 1870-80

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.